Abstract
EXECUTIVES AT THE 2005 CPHI conference in Madrid last week said business in the custom synthesis of active pharmaceutical ingredients (APIs) and advanced intermediates is coming back after a prolonged downturn. The industry's landscape is also shifting, with one traditional player exiting the business, another spinning off fine chemicals, and several stalwarts reorganizing and investing. And there is speculation that consolidation in the sector, which has been oversupplied for more than five years, is not over. SAFC, the fine chemicals business launched by Sigma-Aldrich in 2004, is currently investing $12 million to double capacity at the high-potency API plant in Madison, Wis., that it acquired last year with its purchase of Tetrionics. According to President Frank Wicks, SAFC is also expanding its cytotoxic and bacterial fermentation capability in Jerusalem. Overall, Wicks said, business was up 18% in the first six months of this year, not counting acquisitions. Clariant, which has reorganized ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
